Rznomics, a gene therapy development company, announced that its Phase 1b/2a clinical trial plan (IND) for the administration of liver cancer drug candidate “RZ-001” along with immune-oncology drugs has been recently approved by the Ministry of Food and Drug Safety.

Rznomics plans to evaluate the efficacy and safety of “RZ-001” as a first-line treatment in about 50 patients diagnosed with hepatocellular carcinoma along with the immune-oncology drug ‘Ticentric’ and the targeted therapy ‘Avastin’. ‘Ticentric’ and ‘Avastin’ are Roche’s most widely used anti-cancer drugs for the first-line treatment of hepatocellular carcinoma. Roche will provide Rznomics for the ‘Ticentric’ to be used in this clinical trial.

RZ-001 received MFDS and FDA clinical trial approval for HCC and GBM as a single administration therapy.
Rznomics is conducting an independent clinical trial of RZ-001 in patients with hepatocellular carcinoma.